<DOC>
	<DOC>NCT00199602</DOC>
	<brief_summary>This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients). Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months</brief_summary>
	<brief_title>Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>First line chemotherapy for solid tumor with: Metastatic disease or Involved nodes or Unresectable tumor Indication for Implantable device for central venous access Potential survival &gt; 3 months ECOG performance status 0 to 2 (WHO) Age between 18 and 75 years. Social security guaranteed Normal laboratory assessments (platelets&gt; 100000/mm3, TP 60%, spontaneous TCA with M/T&lt;1.5, TGO and TGP &lt; 2xN, serum creatinin&lt;120Âµmol/l) Informed consent signed Inability to understand informed consent or interfering with compliance for treatment or protocol Anticoagulant treatment related criteria Acute infectious endocarditis History related with heparin allergy or thrombopenia due to heparin Uncontrolled high blood pressure (systolic blood pressure &gt;180 mm Hg and/or diastolic blood pressure &gt;110 mm Hg) Hemorrhagic syndrome ongoing Patient with platelet inhibitors treatment Chronic, daily treatment with anticoagulant therapy (LMWH or AVK), use as preventive or curative level Patient with liver failure (TP&lt;60%) or renal insufficiency (creatinin clearance&lt; 20 ml/mn) Women with pregnancy and lactating Pathologyrelated criteria deep venous thrombosis history or pulmonary embolism (&lt; 6 months) Clinical suspicious of brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>